Zhitong Finance App News, Nuocheng Jianhua (09969.HK) announced that the phase III registered clinical trial of the potent highly selective tyrosine kinase 2 (TYK2) allosteric inhibitor fadeucravacitinib (ICP-488) for the treatment of patients with moderate to severe plaque psoriasis successfully reached its main end.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.